A multicentre analytical comparison study of inter‐reader and inter‐assay agreement of four programmed death‐ligand 1 immunohistochemistry assays for scoring in triple‐negative breast cancer. Issue 4 (27th November 2020)
- Record Type:
- Journal Article
- Title:
- A multicentre analytical comparison study of inter‐reader and inter‐assay agreement of four programmed death‐ligand 1 immunohistochemistry assays for scoring in triple‐negative breast cancer. Issue 4 (27th November 2020)
- Main Title:
- A multicentre analytical comparison study of inter‐reader and inter‐assay agreement of four programmed death‐ligand 1 immunohistochemistry assays for scoring in triple‐negative breast cancer
- Authors:
- Noske, Aurelia
Ammann, Johannes U
Wagner, Daniel‐Christoph
Denkert, Carsten
Lebeau, Annette
Sinn, Peter
Kreipe, Hans‐Heinrich
Sommer, Ulrich
Baretton, Gustavo
Steiger, Katja
Kiechle, Marion
Hieke‐Schulz, Stefanie
Flores, Mike
Roth, Wilfried
Weichert, Wilko - Abstract:
- Abstract : Aims: Studies in various cancer types have demonstrated discordance between results from different programmed death‐ligand 1 (PD‐L1) assays. Here, we compare the reproducibility and analytical concordance of four clinically developed assays for assessing PD‐L1‐positivity in tumour‐infiltrating immune cells in the tumour area (PD‐L1‐IC‐positivity) in triple‐negative breast cancer (TNBC). Methods and results: Primary TNBC resection specimens ( n = 30) were selected based on their PD‐L1‐IC‐positivity per VENTANA SP142 (<1%: 15 cases; 1–5%: seven cases; >5%: eight cases). Serial histological sections were stained for PD‐L1 using VENTANA SP142, VENTANA SP263, DAKO 22C3 and DAKO 28‐8. PD‐L1‐IC‐positivity and tumour cell expression (≥1 versus <1%) were scored by trained readers from seven sites using online virtual microscopy. The adjusted mean of PD‐L1‐IC‐positivity for SP263 (7.8%) was significantly higher than those for the other three assays (3.7–4.9%). Differences in adjusted means were statistically significant between SP263 and the other three assays ( P < 0.0001) but not between the three remaining assays when excluding SP263 ( P = 0.0961–0.6522). Intra‐class correlation coefficients revealed moderate‐to‐strong inter‐reader agreement for each assay (0.460–0.805) and poor‐to‐strong inter‐assay agreement for each reader (0.298–0.678) on PD‐L1‐IC‐positivity. Conclusions: In this first multicentre study of different PD‐L1 assays in TNBC, we show thatAbstract : Aims: Studies in various cancer types have demonstrated discordance between results from different programmed death‐ligand 1 (PD‐L1) assays. Here, we compare the reproducibility and analytical concordance of four clinically developed assays for assessing PD‐L1‐positivity in tumour‐infiltrating immune cells in the tumour area (PD‐L1‐IC‐positivity) in triple‐negative breast cancer (TNBC). Methods and results: Primary TNBC resection specimens ( n = 30) were selected based on their PD‐L1‐IC‐positivity per VENTANA SP142 (<1%: 15 cases; 1–5%: seven cases; >5%: eight cases). Serial histological sections were stained for PD‐L1 using VENTANA SP142, VENTANA SP263, DAKO 22C3 and DAKO 28‐8. PD‐L1‐IC‐positivity and tumour cell expression (≥1 versus <1%) were scored by trained readers from seven sites using online virtual microscopy. The adjusted mean of PD‐L1‐IC‐positivity for SP263 (7.8%) was significantly higher than those for the other three assays (3.7–4.9%). Differences in adjusted means were statistically significant between SP263 and the other three assays ( P < 0.0001) but not between the three remaining assays when excluding SP263 ( P = 0.0961–0.6522). Intra‐class correlation coefficients revealed moderate‐to‐strong inter‐reader agreement for each assay (0.460–0.805) and poor‐to‐strong inter‐assay agreement for each reader (0.298–0.678) on PD‐L1‐IC‐positivity. Conclusions: In this first multicentre study of different PD‐L1 assays in TNBC, we show that PD‐L1‐IC‐positivity for SP142, 22C3 and 28‐8 was reproducible and analytically concordant, indicating that these three assays may be analytically interchangeable. The relevance of the higher PD‐L1‐IC‐positivity for SP263 should be further investigated. … (more)
- Is Part Of:
- Histopathology. Volume 78:Issue 4(2021)
- Journal:
- Histopathology
- Issue:
- Volume 78:Issue 4(2021)
- Issue Display:
- Volume 78, Issue 4 (2021)
- Year:
- 2021
- Volume:
- 78
- Issue:
- 4
- Issue Sort Value:
- 2021-0078-0004-0000
- Page Start:
- 567
- Page End:
- 577
- Publication Date:
- 2020-11-27
- Subjects:
- immunohistochemistry -- inter‐assay agreement -- inter‐reader agreement -- programmed death‐ligand 1 -- triple‐negative breast cancer
Histology, Pathological -- Periodicals
611.018 - Journal URLs:
- http://www.blackwell-synergy.com/member/institutions/issuelist.asp?journal=his ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2559 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/his.14254 ↗
- Languages:
- English
- ISSNs:
- 0309-0167
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4316.027000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 16849.xml